Ayala Pharmaceuticals, Inc. (ADXS)
OTCMKTS
· Delayed Price · Currency is USD
0.105
0.00 (0.00%)
Dec 3, 2024, 4:00 PM EST
Ayala Pharmaceuticals Revenue
In the year 2023, Ayala Pharmaceuticals had annual revenue of $13.00K, down -98.12%.
Revenue
13.00K
Revenue Growth
-98.12%
P/S Ratio
12.51
Revenue / Employee
619.05
Employees
21
Market Cap
1.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 13.00K | -679.00K | -98.12% |
| Dec 31, 2022 | 692.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAyala Pharmaceuticals News
- 7 months ago - Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting Obligations - GlobeNewsWire
- 9 months ago - Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome - GlobeNewsWire
- 10 months ago - Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors - Business Wire
- 10 months ago - Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals - Business Wire
- 1 year ago - Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023 - GlobeNewsWire
- 1 year ago - Ayala Pharmaceuticals Announces Closing of Merger with Biosight - GlobeNewsWire
- 1 year ago - Ayala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - Ayala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023 - GlobeNewsWire